View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Guy Sips ... (+8)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, AD NA, ATEB BB, FUR NA, IBAB BB, JEN BB, SOLB ...

: ABI BB, AD NA, ATEB BB, FUR NA, IBAB BB, JEN BB, SOLB BB, AZE BB, MAAT FP, CTPNV NA, DEME BB

Jacob Mekhael
  • Jacob Mekhael

ASH abstracts Autolus, Galapagos, MaaT

The abstracts for presentations at ASH (7-10 December) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (digging deeper into the obe-cel dataset), Galapagos (more CAR-T data and pre-clinical data on TCR-T) and MaaT (early access program in aGvHD):

 PRESS RELEASE

Galapagos to Present Results of Pioneering Innovation in Cancer Cell T...

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will spotlight our cutting-e...

 PRESS RELEASE

Galapagos presenteert resultaten van baanbrekende innovatie in kankerc...

Galapagos presenteert resultaten van baanbrekende innovatie in kankerceltherapie op ASH 2024 Nieuwe fase 1/2 resultaten ondersteunen het potentieel van onze CAR T-celtherapiekandidaten, GLPG5101 en GLPG5201, om tegemoet te komen aan de onvervulde behoeften bij patiënten met een slechte prognose. Ons innovatieve gedecentraliseerde celtherapieproductieplatform levert verse, fitte cellen binnen een mediane vein-to-vein tijd van zeven dagen, met een bemoedigende impact op de resultaten voor patiënten. Drie abstracts, waaronder een mondelinge presentatie voor GLPG5101 bij recidief/refractair non...

 PRESS RELEASE

MaaT Pharma publie ses résultats financiers pour le troisième trimestr...

LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd'hui un point sur ses activités et la publication de sa trésorerie et de son chiffre d’affaires jusqu'au 30 septembre 2024. Faits cliniques marquants MaaT013 Hémato-oncologie : En , MaaT Pharma a annoncé que les lots de MaaT013 étaient produits et prêts à êtr...

 PRESS RELEASE

MaaT Pharma Provides Third Quarter 2024 Business and Financial Results...

LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provided a business update and reported its cash position and revenue as of September 30, 2024. Pipeline highlights MaaT013 In hemato-oncology: In , MaaT Pharma announced that MaaT013 batches were ready for distribution for clinical supply in the US and that MaaT Pharma advanced the readiness phase for th...

 PRESS RELEASE

Autolus Therapeutics to Present Clinical Data Updates at the American ...

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations LONDON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces the online publication of four abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held from December 7-10, 2024, in San Diego. “The FELIX study’s rich data set continues to provide importan...

Jacob Mekhael
  • Jacob Mekhael

Galapagos 9M24 conference call feedback

Galapagos hosted a conference call to discuss its 9M24 results. Most noteworthy is that we learned of an R&D day panned for 2025, as well as the deal structure with the company's CAR-T manufacturing partners in the US. We summarise the main takeaways below.

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Galapagos : Sharp ramp-up in R&D costs

>A sharp ramp-up in R&D costs - Galapagos reported yesterday its Q3 earnings after the closure of the US market. Revenues stood at € 60m vs € 70m forecast. These revenues come mainly from the booking of its agreement over 10 years with Gilead. In terms of costs, opex ramp up very sharply in the first 9M of the year.The R&D business is developing as expected following the progress in clinical programs, but costs are proving far higher than forecasts with a s...

Jacob Mekhael
  • Jacob Mekhael

Galapagos Uneventful 9M24 results, new cell therapy data at ASH

Galapagos reported uneventful 9M24 results with a cash position of € 3.3b, and reiterated its FY24 cash burn guidance of € 370-410m (including BD). In the pipeline, we most look forward to new data from the phase 1/2 ATALANTA-1 and EUPLAGIA-1 CAR-T studies at ASH in December 2024, and are keen to see the solid outcomes observed to date confirmed in a larger set of patients and with longer follow up. In addition, the company plans to present pre-clinical data for uza-cel (TCR-T), and we hope to g...

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste

Morning Notes : ABI BB, ARCAD NA, ARGX BB, DIE BB, DSFIR NA, FLOW NA, ...

: ABI BB, ARCAD NA, ARGX BB, DIE BB, DSFIR NA, FLOW NA, GLPG NA, INGA NA, RECT BB

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Galapagos : Une accélération forte des frais de R&D

>Une forte accélération des frais de R&D - Galapagos a publié hier ses résultats du T3 après la fermeture du marché US. Les revenus s’élèvent à 60 M€ vs 70 M€ att. Ces revenus viennent essentiellement de la reconnaissance de son accord portée sur 10 ans avec Gilead. Au niveau des couts, les Opex accélèrent très fortement sur les 9premiers mois de l’année.L’activité de R&D se développe logiquement suite aux avancées des programmes cliniques, mais les coûts s...

 PRESS RELEASE

Galapagos Reports Third Quarter 2024 Financial Results and Provides Bu...

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance of the Investi...

 PRESS RELEASE

Galapagos rapporteert financiële resultaten over het derde kwartaal va...

Galapagos rapporteert financiële resultaten over het derde kwartaal van 2024 en geeft een bedrijfsupdate We bouwen onze pijplijn en versnellen innovatie door gerichte uitvoering van onze Forward, Faster strategie.We streven ernaar te voorzien in de grote onvervulde behoeften van patiënten met onze groeiende pijplijn van celtherapie en kleine moleculen met doorbraakpotentieel. Deze omvat meer dan 20 programma’s, met vier kandidaat-producten in klinische ontwikkeling in 11 indicaties, en meer dan 15 preklinische programma's in oncologie en immunologie. We bereikten een belangrijke regelgevend...

 PRESS RELEASE

Autolus Therapeutics to Report Third Quarter 2024 Financial Results an...

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a g...

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Wim Lewi
 PRESS RELEASE

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphom...

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress Findings suggest the potential for obe-cel treatment without the need for consolidative SCTObe-cel given as a sole treatment to patients with lower tumor burden at lymphodepletion was associated with better outcomes LONDON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces a poster presentation at the 2024 Lymphoma, Leukemia & Myeloma Congress being held ...

Thibault Leneeuw ... (+4)
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch